Get the Stockscreener App
3.8299
2.69%
-0.1101
X 4 Pharmaceuticals Inc stock is traded at $3.8299, with a volume of 23,738.
It is down -2.69% in the last 24 hours and down -10.63% over the past month.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
See More
Previous Close:
$3.94
Open:
$3.99
24h Volume:
23,738
Relative Volume:
0.05
Market Cap:
$362.19M
Revenue:
$35.11M
Net Income/Loss:
$-79.20M
P/E Ratio:
-0.8831
EPS:
-4.3367
Net Cash Flow:
$-88.62M
1W Performance:
-14.80%
1M Performance:
-10.63%
6M Performance:
+6.50%
1Y Performance:
+31.30%
1-Day Range:
$3.82
$3.99
1-Week Range:
$3.85
$4.50
52-Week Range:
$1.35
$4.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Name
X 4 Pharmaceuticals Inc
Sector
Industry
Phone
857-529-8300
Address
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
3.84 | 371.62M | 35.11M | -79.20M | -88.62M | -4.3367 |
VRTX
Vertex Pharmaceuticals Inc
|
435.99 | 110.90B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
625.98 | 73.20B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
788.24 | 49.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.01 | 38.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
143.13 | 30.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-09-26 | Initiated | Guggenheim | Buy |
| Dec-05-25 | Resumed | Stifel | Buy |
| Dec-12-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Aug-30-23 | Resumed | B. Riley Securities | Buy |
| Dec-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | ROTH Capital | Buy |
| Dec-09-19 | Upgrade | Citigroup | Neutral → Buy |
| Dec-05-19 | Initiated | B. Riley FBR | Buy |
| Jun-07-19 | Initiated | Stifel | Buy |
| Jun-05-19 | Initiated | Cowen | Outperform |
View All
X 4 Pharmaceuticals Inc Stock (XFOR) Latest News
[EFFECT] X4 Pharmaceuticals, Inc SEC Filing - Stock Titan
Perceptive group holds 7.3% of X4 Pharmaceuticals (NASDAQ: XFOR) with exercisable warrants - Stock Titan
ANIP Valuation: Does 9.8x Forward P/E Offer Upside? - TradingView
This Insider Has Just Sold Shares In X4 Pharmaceuticals - simplywall.st
Apellis (NASDAQ: APLS) director tenders shares for $41 cash plus CVR - Stock Titan
Biogen deal: Apellis (APLS) VP tenders 65,955 shares, options cancelled - Stock Titan
Apellis (NASDAQ: APLS) director cashes out shares and options in Biogen tender offer - Stock Titan
[Form 4] Apellis Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Biogen buys Apellis (APLS) for $41 cash plus CVR per share - Stock Titan
Biogen to acquire Apellis (NASDAQ: APLS) for $41 per share plus CVR - Stock Titan
Biogen deal: Apellis (APLS) director’s shares and options cashed out - Stock Titan
Biogen buys Apellis (NASDAQ: APLS) at $41 per share plus CVR - Stock Titan
Apellis (NASDAQ: APLS) director fully cashes out in Biogen merger swap - Stock Titan
Here is Why X4 Pharmaceuticals (XFOR) is Among the Unrivaled Penny Stocks to Buy Now - Yahoo Finance
X4 Pharmaceuticals (XFOR) corrects director nominee and expands equity plan - Stock Titan
X4 Pharma CFO Kirske sells $72,820 in common stock - Investing.com
X4 Pharmaceuticals (XFOR) CFO sells shares to cover tax obligation - Stock Titan
[144] X4 Pharmaceuticals, Inc SEC Filing - Stock Titan
Shareholders at X4 Pharmaceuticals (NASDAQ: XFOR) approve equity plan - Stock Titan
5 Unrivaled Penny Stocks to Buy Now - Insider Monkey
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
XFOR (X4 Pharmaceuticals) beats Q1 2026 EPS estimates by 21.6 percent, shares climb 3 percent.Collaborative Trading Signals - newser.com
How X4 Pharmaceuticals (XFOR) is positioning for the next five years (Bearish Sentiment) 2026-05-08Shared Momentum Picks - newser.com
Major holder Artal group converts LXRX (LXRX) Series B preferred into 20.4M common shares - Stock Titan
Best Pharmaceutical Stocks for 2026 and How to Invest - The Motley Fool
CapEx per share of X4 Pharmaceuticals, Inc. – FWB:48Q0 - TradingView
EBIT per share of X4 Pharmaceuticals, Inc. – FWB:48Q0 - TradingView
X4 pharmaceuticals incmay offer up to $300 million of common stock, preferred stock, debt securities, warrants, and/or unitsSEC filing - marketscreener.com
X4 Pharmaceuticals IncMay Offer Up To $300 Million Of Common Stock, Preferred Stock, Debt Securities, Warrants, And/Or UnitsSEC Filing - TradingView
X4 Pharmaceuticals (NASDAQ: XFOR) files $300M shelf; $75M ATM with Jefferies - Stock Titan
X4 Pharmaceuticals, Inc. Q1 2026 Financial Results and Forward-Looking Statements – Quarterly Report Highlights - Minichart
X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
X4 Pharmaceuticals: Q1 Earnings Snapshot - KING5.com
X4 Pharmaceuticals Reports Positive Updates on 4WARD Phase 3 Trial and European Commission Approval for XOLREMDI - Quiver Quantitative
EU authorizes first WHIM syndrome treatment as X4 trial nears enrollment - Stock Titan
X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance
EU approves XOLREMDI as X4 Pharmaceuticals (NASDAQ: XFOR) reports Q1 loss - Stock Titan
X4 Pharmaceuticals Inc (XFOR) - MSN
NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA - ACCESS Newswire
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026 - Business Wire
MSN Money - MSN
Processa (PCSA) CAO Wendy Guy buys 1,748 shares in open-market trade - Stock Titan
Seven new Xenon hires get stock awards priced at $56.04 - Stock Titan
Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity - The Manila Times
Europe authorizes first drug for patients with relentless hunger - Stock Titan
XFOR Stock Price, Quote & Chart | X4 PHARMACEUTICALS INC (NASDAQ:XFOR) - ChartMill
Ionis (NASDAQ: IONS) EVP sells 1,626 shares under Rule 10b5-1 plan - Stock Titan
Fierce Biotech Layoff Tracker 2026: Autolus decreases headcount by 13%; Replimune reduces staff - Fierce Biotech
X4 Pharmaceuticals (XFOR) Stock: Directional Bias Review | Q4 2025: Earnings Beat EstimatesCrowd Trend Signals - Newser
$1.9B deal gives Chiesi first oral, on-demand hereditary angioedema treatment - Stock Titan
X4 Pharmaceuticals gets EU approval for WHIM syndrome drug By Investing.com - Investing.com Canada
X 4 Pharmaceuticals Inc Stock (XFOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.44%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):